Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vociprotafib
- Development stage
- Phase 2
- Lead developer
- REVOLUTION Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vociprotafib (SAR442720/RMC-4630) is a potent and orally bioavailable small molecule designed to selectively inhibit the activity of SHP2 (Src homology region 2 domain-containing phosphatase-2), an upstream cellular protein that plays a central role in modulating cell survival and growth by transmitting signals from receptor tyrosine kinases to RAS. It is being investigated as a potential treatment for various RAS-dependent tumors, particularly in combination with other targeted therapies and immunotherapies. The drug is being developed through a collaboration between Revolution Medicines and Sanofi.
- Other names
- VociprotafibRMC 4630RMC4630RMC-4630SAR-442720SAR442720SAR 442720Compound A-290[6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl]methanol
02
Targets
PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)
Beyond the preview
Go deeper on vociprotafib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vociprotafib.